Cancer Antigen-GI (CA 19-9), Body Fluid
Also known as: CA-GI FL
Use
The Cancer Antigen-GI (CA 19-9) test is performed on body fluids and is used in the clinical context of evaluating cancer. It should not be interpreted as absolute evidence of the presence or absence of malignant disease, regardless of the test result level. The test utilizes the Roche CA 19-9 electrochemiluminescent immunoassay method. While it can provide useful information in the context of a complete clinical evaluation, results obtained with different methods or kits cannot be used interchangeably.
Special Instructions
Not provided.
Limitations
The test has not been cleared or approved by the US Food and Drug Administration, and thus is categorized as a Laboratory Developed Test (LDT). Results from this test cannot be used interchangeably with those from other test methods or kits. The test is intended for use in clinical settings and should be interpreted in conjunction with other clinical findings.
New York Approved
Methodology
Immunoassay (ECLIA)
Biomarkers
Cancer Antigen-GI (CA 19-9)
Analyte
LOINC Codes
- 26924-1 - Cancer Ag19-9 Fld-aCnc
- 31208-2 - Specimen source
Result Turnaround Time
1 day
Related Documents
For more information, please review the documents below
Specimen
Body Fluid
Volume
1 mL
Minimum Volume
0.5 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Centrifuge to remove cellular material. Transfer 1 mL body fluid to an ARUP Standard Transport Tube.
Storage Instructions
Refrigerated.
Causes for Rejection
Specimen types other than those listed. Specimens too viscous to be aspirated by instrument.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 8 hours |
| Refrigerated | 5 days |
| Frozen | 3 months |
Other tests from different labs that may be relevant